Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 60.08M | 59.84M | 55.17M | 40.01M | 31.29M | 29.08M |
Gross Profit | 27.43M | 26.27M | 22.00M | 16.46M | 12.89M | 11.34M |
EBITDA | 15.97M | 15.32M | 13.22M | 9.44M | 8.05M | 5.86M |
Net Income | 9.42M | 8.89M | 7.69M | 6.08M | 5.13M | 3.12M |
Balance Sheet | ||||||
Total Assets | 66.27M | 68.23M | 65.55M | 55.56M | 48.37M | 45.17M |
Cash, Cash Equivalents and Short-Term Investments | 8.13M | 12.05M | 10.40M | 6.65M | 5.26M | 3.63M |
Total Debt | 4.57M | 3.38M | 4.31M | 3.51M | 1.44M | 1.94M |
Total Liabilities | 12.07M | 12.69M | 15.97M | 12.21M | 9.27M | 9.53M |
Stockholders Equity | 54.21M | 54.89M | 49.25M | 43.48M | 39.10M | 35.64M |
Cash Flow | ||||||
Free Cash Flow | 9.37M | 6.45M | 7.63M | 2.63M | 3.86M | 3.45M |
Operating Cash Flow | 10.37M | 8.09M | 8.42M | 3.15M | 4.51M | 4.20M |
Investing Cash Flow | -2.03M | -1.64M | -782.43K | -1.11M | -652.62K | -753.41K |
Financing Cash Flow | -8.53M | -4.80M | -3.88M | -648.95K | -2.24M | -3.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | AU$272.64M | 28.66 | 18.04% | 2.03% | 6.00% | 10.26% | |
62 Neutral | $10.37B | 10.13 | 1.50% | 2.95% | 2.32% | -32.65% | |
46 Neutral | AU$100.90M | ― | -30.39% | ― | -41.05% | -122.11% | |
36 Underperform | AU$381.37M | ― | -92.30% | ― | -100.00% | 65.31% | |
36 Underperform | AU$252.03M | ― | -12.08% | ― | ― | 46.56% | |
32 Underperform | AU$393.93M | ― | -38.25% | ― | ― | 20.80% |
XRF Scientific Limited announced a change in the director’s interest, with Vance Stazzonelli acquiring 10,000 ordinary shares, increasing his total to 850,000 shares. This change, executed through a combination of off-market and on-market trades, reflects ongoing adjustments in the company’s leadership investments, potentially impacting stakeholder perceptions and the company’s market dynamics.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.